Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cisplatin |
| Synonyms | |
| Therapy Description |
Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRIP1 C350F | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 C350F in culture (PMID: 33619228). | 33619228 |
| BARD1 P669L | ovarian cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 P669L was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| RAD51C G114R | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C G114R sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 Q685* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 Q685* in culture (PMID: 33619228). | 33619228 |
| RAD51C K131I | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C K131I sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| RAD51C D348V | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C D348V sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 L415P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 L415P in culture (PMID: 33619228). | 33619228 |
| BRIP1 E726* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 E726* in culture (PMID: 33619228). | 33619228 |
| BARD1 P187A | ovarian cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 P187A was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 G491R | ovarian cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 G491R was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BRIP1 Q227* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 Q227* in culture (PMID: 33619228). | 33619228 |
| RAD51C L27P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C L27P sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| RAD51C L138F | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C L138F sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 R762P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 R762P in culture (PMID: 33619228). | 33619228 |
| RAD51C G150E | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C G150E sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 D393V | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 D393V in culture (PMID: 33619228). | 33619228 |
| BARD1 G753D | cervical cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, cisplatin treatment of HeLa cells expressing Bard1 G753D were more sensitive than wild-type Bard1 expressing cells, as demonstrated by decreased colony formation (PMID: 30925164). | 30925164 |
| BRIP1 E626K | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 E626K in culture (PMID: 33619228). | 33619228 |
| BRIP1 K52R | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 K52R in culture (PMID: 33619228). | 33619228 |
| RAD51C D108G | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C D108G sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| RAD51C C135Y | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C C135Y sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 G690R | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 G690R in culture (PMID: 33619228). | 33619228 |
| BRIP1 G690E | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 G690E in culture (PMID: 33619228). | 33619228 |
| RAD51C R312W | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C R312W sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 S614Y | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 S614Y in culture (PMID: 33619228). | 33619228 |
| BRIP1 Y147* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 Y147* in culture (PMID: 33619228). | 33619228 |
| BRIP1 L347P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 L347P in culture (PMID: 33619228). | 33619228 |
| BRIP1 G49* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 G49* in culture (PMID: 33619228). | 33619228 |
| BRIP1 Q25* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 Q25* in culture (PMID: 33619228). | 33619228 |
| BRIP1 Q645* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 Q645* in culture (PMID: 33619228). | 33619228 |
| BARD1 P187A | breast cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 P187A was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 R112* | neuroblastoma | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a neuroblastoma cell line expressing BARD1 R112* culture (PMID: 37688570). | 37688570 |
| BRIP1 S618* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 S618* in culture (PMID: 33619228). | 33619228 |
| BARD1 V85M | breast cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 V85M was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| CDK12 dec exp | ovarian cancer | sensitive | Cisplatin | Preclinical | Actionable | In a preclinical study, the depletion of CDK12 in an ovarian cancer cell line by siRNAs resulted in the depletion of BRCA1 and sensitized the cells to the cross-linking agents Alkeran (melphalan), Platinol (cisplatin), and the PARP inhibitor veliparib (ABT-888) (PMID: 24554720). | 24554720 |
| RAD51C S163R | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C S163R sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BARD1 Q730L | ovarian cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 Q730L was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BRIP1 S189L | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 S189L in culture (PMID: 33619228). | 33619228 |
| FANCA S1088F | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, overexpression of FANCA S1088F in FANCA-null cells derived from Fanconi anemia patients resulted in increased sensitivity to Platinol (cisplatin) compared to wild-type Fanca expression in culture (PMID: 28864460). | 28864460 |
| BRIP1 P785L | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 P785L in culture (PMID: 33619228). | 33619228 |
| RAD51C T102I | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C T102I sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| PALB2 dec exp | triple-receptor negative breast cancer | sensitive | Cisplatin | Preclinical | Actionable | In a preclinical study, knockdown of PALB2 enhanced growth inhibition by Platinol (cisplatin) in triple-negative breast cancer cell lines in culture (PMID: 25193512). | 25193512 |
| RAD51C G125V | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C G125V sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 A349P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 A349P in culture (PMID: 33619228). | 33619228 |
| BRIP1 L340R | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 L340R in culture (PMID: 33619228). | 33619228 |
| BRIP1 G224* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 G224* in culture (PMID: 33619228). | 33619228 |
| BRIP1 G49R | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 G49R in culture (PMID: 33619228). | 33619228 |
| BRIP1 W335L | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 W335L in culture (PMID: 33619228). | 33619228 |
| BRIP1 Y461* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 Y461* in culture (PMID: 33619228). | 33619228 |
| RAD51C A279P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C A279P sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| RAD51C T132I | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C T132I sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BARD1 P707S | cervical cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, cisplatin treatment of HeLa cells expressing Bard1 P707S were more sensitive than wild-type Bard1 expressing cells, as demonstrated by decreased colony formation (PMID: 30925164). | 30925164 |
| RAD51C D159A | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C D159A sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 Q126* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 Q126* in culture (PMID: 33619228). | 33619228 |
| BRIP1 T252R | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 T252R in culture (PMID: 33619228). | 33619228 |
| BRIP1 G763C | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 G763C in culture (PMID: 33619228). | 33619228 |
| BARD1 V85M | ovarian cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 V85M was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| RAD51C G153D | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C G153D sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 V341D | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 V341D in culture (PMID: 33619228). | 33619228 |
| BRIP1 Q815* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 Q815* in culture (PMID: 33619228). | 33619228 |
| RAD51C G130R | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C G130R sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BARD1 R565C | breast cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 R565C was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BRIP1 E795* | Advanced Solid Tumor | resistant | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment did not inhibit viability of a cell line expressing BRIP1 E795* in culture (PMID: 33619228). | 33619228 |
| BRIP1 R831K | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 R831K in culture (PMID: 33619228). | 33619228 |
| BRIP1 S990A | Advanced Solid Tumor | no benefit | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment did not inhibit viability of a cell line expressing BRIP1 S990A in culture (PMID: 33619228). | 33619228 |
| BRIP1 G51* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 G51* in culture (PMID: 33619228). | 33619228 |
| BRIP1 E357* | Advanced Solid Tumor | resistant | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment did not inhibit viability of a cell line expressing BRIP1 E357* in culture (PMID: 33619228). | 33619228 |
| RAD51C G114V | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C G114V sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 W448* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 W448* in culture (PMID: 33619228). | 33619228 |
| RAD51C G162E | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C G162E sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 F366S | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 F366S in culture (PMID: 33619228). | 33619228 |
| BRIP1 R836* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 R836* in culture (PMID: 33619228). | 33619228 |
| BARD1 V767fs | cervical cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, cisplatin treatment of HeLa cells expressing Bard1 P707S were more sensitive than wild-type Bard1 expressing cells, as demonstrated by decreased colony formation (PMID: 30925164). | 30925164 |
| BARD1 T719R | breast cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 T719R was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| RAD51C T132R | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C T132R sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 S772* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 S772* in culture (PMID: 33619228). | 33619228 |
| RAD51C R168G | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C R168G sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 Q561* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 Q561* in culture (PMID: 33619228). | 33619228 |
| BRIP1 E81* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 E81* in culture (PMID: 33619228). | 33619228 |
| BRIP1 S697P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 S697P in culture (PMID: 33619228). | 33619228 |
| RAD51C V140E | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C V140E sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 S653* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 S653* in culture (PMID: 33619228). | 33619228 |
| RAD51C G302V | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C G302V sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BARD1 Q730L | breast cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 Q730L was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| RAD51C D242N | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C D242N sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 R261* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 R261* in culture (PMID: 33619228). | 33619228 |
| RAD51C Q133E | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C Q133E sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| RAD51C T336P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C T336P sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| RAD51C V156D | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C V156D sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BARD1 E287fs | neuroblastoma | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a neuroblastoma cell line expressing BARD1 E287fs culture (PMID: 37688570). | 37688570 |
| BARD1 T719R | ovarian cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 T719R was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BRIP1 S697F | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 S697F in culture (PMID: 33619228). | 33619228 |
| BARD1 A460T | cervical cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, cisplatin treatment of HeLa cells expressing Bard1 A460T were more sensitive than wild-type Bard1 expressing cells, as demonstrated by decreased colony formation (PMID: 30925164). | 30925164 |
| BRIP1 E387* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 E387* in culture (PMID: 33619228). | 33619228 |
| BRIP1 L860P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 L860P in culture (PMID: 33619228). | 33619228 |
| RAD51C D159Y | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C D159Y sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 Q689* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 Q689* in culture (PMID: 33619228). | 33619228 |
| BRIP1 R439* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 R439* in culture (PMID: 33619228). | 33619228 |
| BARD1 P669L | breast cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 P669L was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| RAD51C A155E | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C A155E sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BARD1 Q564* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BARD1 Q564* culture (PMID: 37688570). | 37688570 |
| RAD51C R237P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C R237P sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| BRIP1 L358P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 L358P in culture (PMID: 33619228). | 33619228 |
| BRIP1 R581* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 R581* in culture (PMID: 33619228). | 33619228 |
| BRIP1 S805* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 S805* in culture (PMID: 33619228). | 33619228 |
| BRIP1 H396D | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a cell line expressing BRIP1 H396D in culture (PMID: 33619228). | 33619228 |
| BARD1 G491R | breast cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, a breast cancer cell line expressing BARD1 G491R was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
| BARD1 R565C | ovarian cancer | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian cancer cell line expressing BARD1 R565C was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837). | 39387837 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT00980954 | Phase III | Carboplatin + Paclitaxel Cisplatin | Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy | Active, not recruiting | USA | CAN | 2 |
| NCT01128387 | Phase Ib/II | Fluorouracil Panitumumab Cisplatin | Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer | Terminated | USA | 0 |
| NCT01064479 | Phase II | Erlotinib Carboplatin Docetaxel Cisplatin | Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck | Completed | USA | 0 |
| NCT02365766 | Phase Ib/II | Cisplatin Pembrolizumab Gemcitabine | Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer | Completed | USA | 0 |
| NCT04459715 | Phase III | Cisplatin + Xevinapant Cisplatin | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) | Terminated | USA | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
| NCT02128906 | Phase II | Cetuximab + Docetaxel Cisplatin | Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design | Recruiting | USA | 0 |
| NCT03819465 | Phase I | Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Disodium Nab-paclitaxel Danvatirsen + Durvalumab Cisplatin Durvalumab | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) | Active, not recruiting | USA | POL | ESP | BEL | AUT | 4 |
| NCT02489903 | Phase II | Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel | RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens | Completed | USA | 0 |
| NCT02477826 | Phase III | Nivolumab Cisplatin Ipilimumab Pemetrexed Disodium Carboplatin Gemcitabine | An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | ROU | POL | NLD | LBN | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
| NCT01898494 | Phase II | Cisplatin Carboplatin | Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer | Active, not recruiting | USA | 0 |
| NCT02635360 | Phase II | Cisplatin Pembrolizumab | Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer | Active, not recruiting | USA | 0 |
| NCT04221945 | Phase III | Cisplatin + Pembrolizumab Cisplatin | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11) | Active, not recruiting | USA | TUR | SWE | NOR | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 11 |
| NCT04892875 | Phase I | Cisplatin + Zimberelimab Cisplatin Cisplatin + Etrumadenant + Zimberelimab | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN) | Withdrawn | 0 | |
| NCT01240590 | Phase Ib/II | Cisplatin + Crolibulin Cisplatin | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | Completed | USA | 0 |
| NCT01042522 | Phase II | Carboplatin Cisplatin Paclitaxel Etoposide Bleomycin | Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors | Unknown status | USA | 0 |
| NCT02429466 | Phase I | Cisplatin Guadecitabine | Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors | Completed | USA | 0 |
| NCT03765918 | Phase III | Pembrolizumab Cisplatin + Pembrolizumab Cisplatin | Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | Active, not recruiting | USA | POL | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
| NCT01454102 | Phase I | Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | Completed | USA | CAN | 0 |
| NCT02041533 | Phase III | Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | Completed | USA | TUR | SWE | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
| NCT01218048 | Phase II | Cisplatin Carboplatin Cetuximab | ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
| NCT06005324 | Phase I | Cisplatin Cisplatin + Fluorouracil + Hydroxyurea Carboplatin + Cetuximab + Paclitaxel | Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer | Recruiting | USA | 0 |
| NCT05583188 | FDA approved | Cisplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Nivolumab Carboplatin Cisplatin + Nivolumab + Paclitaxel Carboplatin + Docetaxel + Nivolumab Cisplatin Carboplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Paclitaxel Pemetrexed Disodium Vinorelbine Gemcitabine Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium | Neoadjuvant Aliya PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC (VIGOR) | Terminated | USA | 0 |
| NCT01732640 | Phase Ib/II | Afatinib + Carboplatin + Paclitaxel Cisplatin | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | Terminated | USA | 0 |
| NCT01014598 | Phase I | Cisplatin | Cisplatin in Treating Patients With Lung Cancer | Completed | USA | 0 |
| NCT02551159 | Phase III | Cisplatin Durvalumab Carboplatin + Cetuximab + Fluorouracil Tremelimumab | Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN | Completed | USA | SVK | ROU | POL | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | 9 |
| NCT03040999 | Phase III | Cisplatin + Pembrolizumab Cisplatin | Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) | Completed | USA | TUR | POL | NZL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 4 |
| NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
| NCT00989651 | Phase I | Bevacizumab + Veliparib Carboplatin Paclitaxel Cisplatin | Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Completed | USA | 0 |
| NCT06946797 | Phase II | Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Ipilimumab + Nivolumab | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (CheckMate-1533) | Not yet recruiting | USA | TUR | ROU | POL | ITA | GRC | FRA | BRA | 3 |
| NCT02349958 | Phase II | Mitomycin C Cisplatin Doxorubicin | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy | Unknown status | USA | 0 |
| NCT01336842 | Phase I | Cisplatin Panobinostat Pemetrexed Disodium | Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | Completed | USA | 0 |
| NCT02537223 | Phase I | Alpelisib Cisplatin | Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer | Completed | CAN | 0 |
| NCT04989283 | Phase II | Carboplatin Atezolizumab + Cisplatin Atezolizumab + Paclitaxel Atezolizumab + Etoposide Cisplatin Etoposide Paclitaxel Atezolizumab + Carboplatin | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | Withdrawn | USA | 0 |
| NCT03811015 | Phase II | Cisplatin Nivolumab Cisplatin + Nivolumab | Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer | Suspended | USA | 0 |
| NCT02855944 | Phase III | Cisplatin Rucaparib Carboplatin Gemcitabine Paclitaxel | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Completed | USA | POL | ITA | ISR | HUN | GBR | ESP | CZE | CAN | BRA | 2 |
| NCT03057106 | Phase II | Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium | Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC | Active, not recruiting | CAN | AUS | 0 |
| NCT02196168 | Phase II | Adavosertib Cisplatin | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Terminated | CAN | 0 |
| NCT02296684 | Phase II | Pembrolizumab Cisplatin | Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT03220932 | Phase III | Bevacizumab Cisplatin | Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer (HIPOVA-01) | Unknown status | FRA | 0 |
| NCT01450761 | Phase III | Cisplatin Ipilimumab Carboplatin Etoposide | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | Completed | USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 13 |
| NCT03387085 | Phase Ib/II | ETBX-051 Aldoxorubicin ETBX-061 Cisplatin Cyclophosphamide haNK cells GI-4000 Bevacizumab Nogapendekin alfa inbakicept Fluorouracil ETBX-011 Oxaliplatin Capecitabine Leucovorin GI-6301 Nab-paclitaxel Avelumab GI-6207 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | Terminated | USA | 0 |
| NCT02734537 | Phase II | Cisplatin | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Recruiting | USA | 0 |
| NCT01810913 | Phase II | Docetaxel Cisplatin Cetuximab + Docetaxel Atezolizumab + Cetuximab | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | Recruiting | USA | CAN | 1 |
| NCT03141359 | Phase II | Paclitaxel Cisplatin Durvalumab Carboplatin Etoposide | Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC | Active, not recruiting | USA | 0 |
| NCT05743270 | Phase II | Cisplatin Nivolumab Cisplatin + RP3 Carboplatin + Paclitaxel + RP3 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | Withdrawn | USA | POL | GRC | GBR | FRA | ESP | DEU | CZE | 0 |
| NCT04595565 | Phase III | Sacituzumab govitecan-hziy Cisplatin Carboplatin Capecitabine | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA) | Active, not recruiting | IRL | FRA | ESP | DEU | CHE | BEL | AUT | 0 |
| NCT04711824 | Phase Ib/II | Nab-paclitaxel Carboplatin + Gemcitabine Cisplatin Durvalumab + Olaparib Paclitaxel Capecitabine Gemcitabine Carboplatin Eribulin | Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (SOLARA) | Recruiting | USA | 0 |
| NCT02595905 | Phase II | Cisplatin Cisplatin + Veliparib | Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases | Completed | USA | 1 |
| NCT06770582 | Phase II | Fluorouracil + Mitomycin C Gemcitabine Pembrolizumab Cisplatin | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | Recruiting | USA | 0 |
| NCT02402920 | Phase I | Carboplatin + Etoposide + Pembrolizumab Cisplatin | Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT01285037 | Phase I | Cisplatin Cetuximab Merestinib | A Study of LY2801653 in Advanced Cancer | Completed | USA | 0 |
| NCT02409355 | Phase III | Carboplatin Cisplatin Gemcitabine Atezolizumab | A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer | Terminated | USA | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | 3 |
| NCT06706401 | Phase III | Cisplatin Cetuximab Tretinoin | Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma (Lysari) | Recruiting | FRA | 0 |
| NCT06607185 | Phase I | Leucovorin Cisplatin Nab-paclitaxel LY4066434 Oxaliplatin Irinotecan Carboplatin Gemcitabine Fluorouracil Cetuximab Pemetrexed Disodium Pembrolizumab | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | 3 |
| NCT06940180 | Phase II | Carboplatin + Docetaxel + Toripalimab-tpzi Toripalimab-tpzi Cisplatin | Toripalimab With Chemotherapy for Sinus Cancer | Not yet recruiting | USA | 0 |
| NCT02508246 | Phase I | Adavosertib Docetaxel Cisplatin | AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck | Completed | USA | 0 |
| NCT01982448 | Phase II | Paclitaxel Cisplatin | Cisplatin vs Paclitaxel for Triple Negative Breast Cancer | Completed | USA | 0 |
| NCT06564844 | Phase III | Tegafur-gimeracil-oteracil Potassium Etoposide AZD2936 + Datopotamab deruxtecan Carboplatin AZD2936 Vinorelbine Pemetrexed Disodium Cisplatin | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) | Recruiting | USA | TUR | SWE | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | 7 |
| NCT02952586 | Phase III | Cisplatin Avelumab + Cisplatin | Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) | Terminated | USA | POL | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT | AUS | 6 |
| NCT03410615 | Phase II | Durvalumab + Tremelimumab Cisplatin Durvalumab | Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC | Active, not recruiting | ITA | ESP | CAN | BEL | 0 |
| NCT03387111 | Phase Ib/II | Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab Nogapendekin alfa inbakicept Fluorouracil ETBX-011 | Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy | Terminated | USA | 0 |
| NCT01820754 | Phase II | Cisplatin Ipilimumab Carboplatin Paclitaxel | Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
| NCT05635708 | Phase II | Nab-paclitaxel Cisplatin BGB-15025 + Tislelizumab BGB-A445 + Tislelizumab Paclitaxel Tislelizumab Carboplatin Pemetrexed Disodium LBL-007 + Tislelizumab | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | Active, not recruiting | USA | ROU | ITA | FRA | ESP | CAN | BRA | AUS | 7 |
| NCT02532192 | Phase I | Rituximab Cisplatin Dexamethasone Cytarabine Fluconazole Belinostat | A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Withdrawn | 0 | |
| NCT02555644 | Phase I | Prexasertib Cisplatin Cetuximab | A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer | Completed | USA | FRA | 0 |
| NCT06431633 | Phase II | Zimberelimab Cisplatin Sacituzumab govitecan-hziy + Zimberelimab Carboplatin | Study of Treatment with Sacituzumab and Zimberelimab for Patients with Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN) | Recruiting | ESP | 0 |
| NCT01409174 | Phase Ib/II | Cisplatin Ipilimumab Aldesleukin Temozolomide Interferon alpha-2b | IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | Terminated | USA | 0 |
| NCT01918306 | Phase Ib/II | Cisplatin Cisplatin + Pictilisib | GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | Terminated | USA | 0 |
| NCT02381535 | Phase I | Cisplatin Onalespib | Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin | Completed | USA | CAN | 0 |
| NCT01859741 | Phase Ib/II | Cisplatin Etoposide Carboplatin Tarextumab | A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE) | Terminated | USA | 0 |
| NCT03576417 | Phase III | Cisplatin Cisplatin + Nivolumab | A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP) | Active, not recruiting | FRA | 0 |
| NCT01836029 | Phase II | Cisplatin Cetuximab + Fluorouracil Carboplatin | Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | 0 |
| NCT02994069 | Phase II | Cisplatin | Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers | Active, not recruiting | USA | 0 |
| NCT04671667 | Phase II | Cisplatin Pembrolizumab Carboplatin | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
| NCT00292955 | Phase II | Cetuximab Cisplatin | Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma | Unknown status | USA | 0 |
| NCT02466971 | Phase III | Cisplatin Cisplatin + Triapine | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | Active, not recruiting | USA | CAN | 1 |
| NCT01927744 | Phase II | Docetaxel + Erlotinib Cisplatin Docetaxel Carboplatin | Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection | Completed | USA | 0 |
| NCT02254278 | Phase II | Cisplatin | Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer | Active, not recruiting | USA | IRL | CAN | 1 |
| NCT01711515 | Phase I | Ipilimumab Cisplatin | Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer | Completed | USA | 0 |
| NCT00492778 | Phase II | Cisplatin | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer | Unknown status | USA | CAN | 0 |
| NCT02107235 | Phase I | Cisplatin Rigosertib Sodium | Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer | Completed | USA | 0 |
| NCT04216290 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Vinblastine Durvalumab + Fluorouracil + Mitomycin C Gemcitabine Fluorouracil + Mitomycin C Durvalumab + Gemcitabine Cisplatin + Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin Durvalumab | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study | Active, not recruiting | USA | 0 |
| NCT00993655 | Phase III | Cisplatin Paclitaxel Carboplatin | Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Completed | USA | GBR | ESP | CAN | 0 |
| NCT06694454 | Phase Ib/II | Carboplatin Pemetrexed Disodium Gemcitabine Azacitidine + Durvalumab Cisplatin Paclitaxel | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) | Not yet recruiting | USA | 0 |
| NCT02201355 | Phase I | Cisplatin | Reduced-Volume Hypofractionated, PET-directed Intensity Modulated Radiotherapy Concurrent With Weekly Cisplatin Chemotherapy for Squamous Cell Carcinoma of the Head and Neck | Terminated | USA | 0 |
| NCT01633541 | Phase II | AT-101 Carboplatin Cisplatin Docetaxel | Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer | Completed | USA | 0 |
| NCT02142738 | Phase III | Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | Completed | 0 | |
| NCT03952585 | Phase II | Nivolumab Cisplatin | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT03770299 | Phase II | Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) | Withdrawn | 0 | |
| NCT03456076 | Phase III | Cisplatin Alectinib Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | Active, not recruiting | USA | TUR | ROU | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | AUT | AUS | 12 |
| NCT04241185 | Phase III | Pembrolizumab Cisplatin Mitomycin C Gemcitabine Fluorouracil | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | Active, not recruiting | USA | TUR | ROU | POL | NLD | LVA | ITA | ISR | HUN | GBR | FRA | EST | ESP | DNK | CZE | AUS | 8 |
| NCT04380636 | Phase III | Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | Active, not recruiting | USA | TUR | ROU | POL | NOR | LVA | LTU | ITA | HUN | GBR | FRA | EST | ESP | DEU | CZE | CAN | ARG | 9 |
| NCT03480672 | Phase II | Cisplatin Cisplatin + Pembrolizumab | Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma | Completed | DEU | 0 |
| NCT05255653 | Phase II | Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) | Recruiting | NLD | GBR | FRA | CAN | 0 |
| NCT02264990 | Phase III | Pemetrexed Disodium Carboplatin Paclitaxel Veliparib Cisplatin | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers | Completed | USA | TUR | NZL | NLD | ISR | HUN | GBR | FIN | ESP | DNK | DEU | CZE | CAN | AUS | ARG | 5 |
| NCT04116047 | Phase III | Cisplatin Cisplatin + Durvalumab | CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) (CompARE) | Active, not recruiting | IRL | GBR | 0 |
| NCT02281955 | Phase II | Cisplatin Carboplatin Cetuximab | De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC | Completed | USA | 0 |
| NCT03631199 | Phase III | Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed Disodium | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1) | Active, not recruiting | USA | TUR | SWE | SVK | ROU | POL | NOR | NLD | LBN | ITA | ISL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUT | AUS | ARG | 15 |
| NCT03107182 | Phase II | Dexamethasone + Diphenhydramine + Famotidine + Fluorouracil + Hydroxyurea + Paclitaxel Carboplatin + Nab-paclitaxel + Nivolumab Cisplatin Carboplatin + Nivolumab + Paclitaxel Nivolumab | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer (OPTIMA-II) | Completed | USA | 0 |
| NCT02314117 | Phase III | Capecitabine Fluorouracil Cisplatin Ramucirumab | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer | Completed | USA | POL | NLD | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | ARG | 4 |
| NCT01101451 | Phase III | Cisplatin | Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery | Completed | USA | 2 |
| NCT02985658 | Phase I | Cisplatin Veliparib Vinorelbine | Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer | No longer available | USA | 0 |
| NCT05608369 | Phase II | Cisplatin Cisplatin + Vorinostat | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC (HPV) | Withdrawn | USA | 0 |
| NCT04658862 | Phase III | Cisplatin Cetrelimab + TAR-200 Gemcitabine | A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | Active, not recruiting | USA | TUR | POL | ITA | HUN | GRC | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
| NCT02409342 | Phase III | Atezolizumab Carboplatin Pemetrexed Disodium Cisplatin | A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | TUR | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | BRA | 7 |
| NCT06623422 | Phase III | Paclitaxel Intismeran autogene + Pembrolizumab Gemcitabine Carboplatin Pembrolizumab Pemetrexed Disodium Cisplatin | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | Recruiting | USA | TUR | SWE | ROU | POL | NZL | NLD | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CAN | BRA | BGR | BEL | AUS | ARG | 6 |
| NCT02394652 | Phase II | Cisplatin Metformin | The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer | Completed | CAN | 0 |
| NCT03126916 | Phase III | Doxorubicin 131I-MIBG Sargramostim Etoposide Melphalan Busulfan Isotretinoin Vincristine Sulfate Cisplatin Cyclophosphamide Thiotepa Dexrazoxane Lorlatinib Carboplatin Aldesleukin Topotecan Dinutuximab | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Active, not recruiting | USA | CAN | 1 |
| NCT01553942 | Phase II | Afatinib Cisplatin Pemetrexed Disodium | Afatinib With CT and RT for EGFR-Mutant NSCLC | Active, not recruiting | USA | 0 |
| NCT05492123 | Phase II | Ipilimumab + Nivolumab Cisplatin Cisplatin + Nivolumab Carboplatin + Nivolumab Carboplatin | Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer | Recruiting | BRA | 0 |
| NCT04486833 | Phase Ib/II | Osimertinib + Quaratusugene Ozeplasmid Carboplatin Cisplatin | Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1) | Recruiting | USA | 0 |
| NCT03612791 | Phase II | Cisplatin Atezolizumab + Cisplatin | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (ATEZOLACC) | Completed | FRA | 0 |
| NCT02358031 | Phase III | Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | Completed | 0 | |
| NCT02641093 | Phase II | Cisplatin Pembrolizumab | Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT03533582 | Phase II | Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Carboplatin + Cisplatin + Doxorubicin + Etoposide Carboplatin + Cisplatin + Doxorubicin + Irinotecan + Vincristine Sulfate Cisplatin Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | Active, not recruiting | USA | NZL | CAN | AUS | 2 |
| NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
| NCT03004287 | Phase II | Melphalan Carfilzomib Cisplatin Cyclophosphamide Lenalidomide Dexamethasone Daratumumab Bortezomib Etoposide Doxorubicin Thalidomide | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | Active, not recruiting | USA | 0 |
| NCT03349710 | Phase III | Cetuximab Cisplatin Cetuximab + Nivolumab Cisplatin + Nivolumab | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | Completed | USA | TUR | POL | ITA | FRA | ESP | 4 |
| NCT01064921 | Phase I | Cisplatin Vorinostat | Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma | Completed | USA | 0 |
| NCT01737008 | Phase I | Cisplatin Dacomitinib | Study of Dacomitinib With Radiotherapy With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck | Completed | CAN | 0 |
| NCT02576574 | Phase III | Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin | Avelumab in First-line NSCLC (JAVELIN Lung 100) | Completed | USA | TUR | SVK | ROU | POL | NZL | NLD | LTU | LBN | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | EST | ESP | DNK | DEU | CZE | CYP | CAN | BRA | BGR | BEL | AUS | 14 |
| NCT06745882 | Phase II | Nab-paclitaxel Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Paclitaxel | Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC | Recruiting | USA | 0 |
| NCT04106362 | Phase II | Cisplatin Cetuximab + Cisplatin | Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma | Terminated | USA | 0 |
| NCT04364048 | Phase II | Pemetrexed Disodium Durvalumab Paclitaxel Etoposide Docetaxel Carboplatin Cisplatin | Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer | Terminated | USA | 0 |
| NCT03783442 | Phase III | Cisplatin Paclitaxel Tislelizumab Oxaliplatin Fluorouracil Capecitabine | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | Completed | USA | ROU | POL | ITA | GBR | FRA | ESP | DEU | CZE | BEL | AUS | 5 |
| NCT05521997 | Phase II | Cisplatin + Telaglenastat Cisplatin | Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | Not yet recruiting | USA | 0 |
| NCT03017326 | Phase III | Cisplatin Carboplatin + Etoposide Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Carboplatin + Doxorubicin Irinotecan + Vincristine Sulfate Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin | Paediatric Hepatic International Tumour Trial (PHITT) | Active, not recruiting | POL | NOR | NLD | ISR | IRL | GBR | FRA | FIN | ESP | DEU | CZE | CHE | BEL | AUT | 0 |
| NCT01928160 | Phase II | Erlotinib + Pemetrexed Disodium Pemetrexed Disodium Carboplatin Carboplatin + Erlotinib Cisplatin Cisplatin + Erlotinib | Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib | Withdrawn | 0 |
CKB BOOST